Display options
Cite
Hoffmeister JD, Kelm-Nelson CA, Ciucci MR. Manipulation of vocal communication and anxiety through pharmacologic modulation of norepinephrine in the Pink1-/- rat model of Parkinson disease. Behav Brain Res. 2021;418:113642doi: 10.1016/j.bbr.2021.113642.
Hoffmeister, J. D., Kelm-Nelson, C. A., & Ciucci, M. R. (2022). Manipulation of vocal communication and anxiety through pharmacologic modulation of norepinephrine in the Pink1-/- rat model of Parkinson disease. Behavioural brain research, 418113642. https://doi.org/10.1016/j.bbr.2021.113642
Hoffmeister, Jesse D, et al. "Manipulation of vocal communication and anxiety through pharmacologic modulation of norepinephrine in the Pink1-/- rat model of Parkinson disease." Behavioural brain research vol. 418 (2022): 113642. doi: https://doi.org/10.1016/j.bbr.2021.113642
Hoffmeister JD, Kelm-Nelson CA, Ciucci MR. Manipulation of vocal communication and anxiety through pharmacologic modulation of norepinephrine in the Pink1-/- rat model of Parkinson disease. Behav Brain Res. 2022 Feb 10;418:113642. doi: 10.1016/j.bbr.2021.113642. Epub 2021 Oct 28. PMID: 34755639; PMCID: PMC8671235.
Copy Download .nbib Format: NLM
Share it on

Behav Brain Res. 2022 Feb 10;418:113642. doi: 10.1016/j.bbr.2021.113642. Epub 2021 Oct 28.

Manipulation of vocal communication and anxiety through pharmacologic modulation of norepinephrine in the Pink1-/- rat model of Parkinson disease.

Behavioural brain research

Jesse D Hoffmeister, Cynthia A Kelm-Nelson, Michelle R Ciucci

Affiliations

  1. Department of Communication Sciences and Disorders, University of Wisconsin-Madison, 1975 Willow Drive, Madison, WI 53706, USA; Department of Surgery, Division of Otolaryngology-Head & Neck Surgery, University of Wisconsin-Madison, 600 Highland Avenue, Madison, WI 53792-7375, USA. Electronic address: [email protected].
  2. Department of Surgery, Division of Otolaryngology-Head & Neck Surgery, University of Wisconsin-Madison, 600 Highland Avenue, Madison, WI 53792-7375, USA. Electronic address: [email protected].
  3. Department of Communication Sciences and Disorders, University of Wisconsin-Madison, 1975 Willow Drive, Madison, WI 53706, USA; Department of Surgery, Division of Otolaryngology-Head & Neck Surgery, University of Wisconsin-Madison, 600 Highland Avenue, Madison, WI 53792-7375, USA; Neuroscience Training Program, University of Wisconsin-Madison, 9531 WIMR II, 1111 Highland Avenue, Madison, WI 53705, USA. Electronic address: [email protected].

PMID: 34755639 PMCID: PMC8671235 DOI: 10.1016/j.bbr.2021.113642

Abstract

Vocal deficits and anxiety are common, co-occurring, and interacting signs of Parkinson Disease (PD) that have a devastating impact on quality of life. Both manifest early in the disease process. Unlike hallmark motor signs of PD, neither respond adequately to dopamine replacement therapies, suggesting that their disease-specific mechanisms are at least partially extra-dopaminergic. Because noradrenergic dysfunction is also a defining feature of PD, especially early in the disease progression, drug therapies targeting norepinephrine are being trialed for treatment of motor and non-motor impairments in PD. Research assessing the effects of noradrenergic manipulation on anxiety and vocal impairment in PD, however, is sparse. In this pre-clinical study, we quantified the influence of pharmacologic manipulation of norepinephrine on vocal impairment and anxiety in Pink1-/- rats, a translational model of PD that demonstrates both vocal deficits and anxiety. Ultrasonic vocalization acoustics, anxiety behavior, and limb motor activity were tested twice for each rat: after injection of saline and after one of three drugs. We hypothesized that norepinephrine reuptake inhibitors (atomoxetine and reboxetine) and a β receptor antagonist (propranolol) would decrease vocal impairment and anxiety compared to saline, without affecting spontaneous motor activity. Our results demonstrated that atomoxetine and reboxetine decreased anxiety behavior. Atomoxetine also modulated ultrasonic vocalization acoustics, including an increase in vocal intensity, which is almost always reduced in animal models and patients with PD. Propranolol did not affect anxiety or vocalization. Drug condition did not influence spontaneous motor activity. These studies demonstrate relationships among vocal impairment, anxiety, and noradrenergic systems in the Pink1-/- rat model of PD.

Copyright © 2021 Elsevier B.V. All rights reserved.

Keywords: Parkinson Disease; Pink1; anxiety; norepinephrine; rat; ultrasonic vocalization

References

  1. Behav Pharmacol. 2008 May;19(3):183-96 - PubMed
  2. Biochem Pharmacol. 2007 Jul 15;74(2):177-90 - PubMed
  3. Physiol Behav. 2003 Oct;80(1):81-8 - PubMed
  4. Transl Neurodegener. 2012 Jan 13;1(1):4 - PubMed
  5. Hum Psychopharmacol. 2002 Oct;17(7):329-33 - PubMed
  6. Neurology. 1987 Jan;37(1):42-6 - PubMed
  7. Neuroscience. 2006;138(2):703-14 - PubMed
  8. J Comp Psychol. 1992 Sep;106(3):270-7 - PubMed
  9. J Speech Lang Hear Res. 2011 Feb;54(1):33-46 - PubMed
  10. Cell Tissue Res. 2004 Oct;318(1):121-34 - PubMed
  11. Mov Disord. 2018 Nov;33(11):1777-1791 - PubMed
  12. Eur J Surg. 1996 Jan;162(1):11-4 - PubMed
  13. Biol Psychiatry. 2008 Jun 1;63(11):1007-12 - PubMed
  14. Mol Psychiatry. 2006 Feb;11(2):187-95 - PubMed
  15. Physiol Behav. 2019 Jan 1;198:120-133 - PubMed
  16. Neuroscience. 2018 May 21;379:126-141 - PubMed
  17. J Acoust Soc Am. 2013 Mar;133(3):1637-43 - PubMed
  18. Behav Neurosci. 2009 Apr;123(2):328-36 - PubMed
  19. J Geriatr Psychiatry Neurol. 2015 Sep;28(3):210-7 - PubMed
  20. Parkinsons Dis. 2011;2011:143547 - PubMed
  21. Neuropsychopharmacology. 2008 Apr;33(5):1028-37 - PubMed
  22. J Clin Psychopharmacol. 2002 Aug;22(4):388-92 - PubMed
  23. Eur J Neurosci. 2020 Nov;52(9):4127-4138 - PubMed
  24. J Neurol Sci. 2009 Sep 15;284(1-2):177-8 - PubMed
  25. Brain Res Brain Res Rev. 2003 Apr;42(1):33-84 - PubMed
  26. Eur J Pharmacol. 1999 Aug 27;379(2-3):125-33 - PubMed
  27. Behav Brain Res. 2018 Oct 15;352:81-93 - PubMed
  28. Mov Disord. 2009 Jan 30;24(2):277-82 - PubMed
  29. Brain Res Brain Res Rev. 2004 Apr;45(1):38-78 - PubMed
  30. Epilepsia. 2012 May;53(5):870-8 - PubMed
  31. Behav Brain Res. 2009 Jan 30;197(1):205-9 - PubMed
  32. Nat Protoc. 2007;2(2):322-8 - PubMed
  33. Acta Neurol Scand. 2008 Jan;117(1):26-34 - PubMed
  34. Exp Neurol. 2004 Jun;187(2):418-29 - PubMed
  35. Behav Brain Res. 2013 Apr 15;243:28-37 - PubMed
  36. J Neurochem. 2010 Jul;114(1):259-70 - PubMed
  37. J Neurol Neurosurg Psychiatry. 2013 Jul;84(7):774-83 - PubMed
  38. Physiol Behav. 2021 Feb 1;229:113248 - PubMed
  39. J Commun Disord. 2011 Sep-Oct;44(5):549-56 - PubMed
  40. J Neurosci Methods. 1985 Aug;14(3):149-67 - PubMed
  41. J Commun Disord. 1975 Sep;8(3):271-9 - PubMed
  42. J Geriatr Psychiatry Neurol. 1999 Summer;12(2):49-52 - PubMed
  43. Am J Psychiatry. 1965 Nov;122(5):509-22 - PubMed
  44. J Pharmacol Exp Ther. 1999 Aug;290(2):761-7 - PubMed
  45. Behav Brain Res. 2005 Apr 15;159(1):73-88 - PubMed
  46. J Neural Transm (Vienna). 2016 Apr;123(4):379-87 - PubMed
  47. Physiol Behav. 2000 Jul 1-15;70(1-2):67-80 - PubMed
  48. J Speech Lang Hear Res. 2017 Mar 1;60(3):507-524 - PubMed
  49. Pediatr Int. 2016 Jun;58(6):476-81 - PubMed
  50. J Speech Lang Hear Res. 2015 Aug;58(4):1134-44 - PubMed
  51. J Neural Transm (Vienna). 2017 Mar;124(3):303-334 - PubMed
  52. Soc Neurosci. 2016;11(4):365-79 - PubMed
  53. Mov Disord. 2014 Dec;29(14):1710-9 - PubMed
  54. Neuropsychopharmacology. 2019 Apr;44(5):859-868 - PubMed
  55. Behav Brain Res. 2021 Sep 24;414:113514 - PubMed
  56. J Parkinsons Dis. 2020;10(2):489-504 - PubMed
  57. J Basic Clin Pharm. 2016 Mar;7(2):27-31 - PubMed
  58. Lancet. 2019 Feb 23;393(10173):768-777 - PubMed
  59. J Parkinsons Dis. 2015;5(4):749-63 - PubMed
  60. J Psychopharmacol. 2016 Feb;30(2):128-39 - PubMed
  61. Mov Disord. 2011 Jun;26(7):1198-1205 - PubMed
  62. Sci Rep. 2019 Mar 27;9(1):5262 - PubMed
  63. Ann Clin Transl Neurol. 2015 Oct;2(10):949-59 - PubMed
  64. Mov Disord. 2010 May 15;25(7):838-45 - PubMed
  65. Physiol Behav. 2008 Mar 18;93(4-5):766-76 - PubMed
  66. Folia Phoniatr Logop. 1994;46(1):9-17 - PubMed
  67. J Clin Psychiatry. 1987 Sep;48(9):355-8 - PubMed
  68. Pharmacol Biochem Behav. 1996 May;54(1):21-30 - PubMed
  69. Clin Neuropharmacol. 2001 Mar-Apr;24(2):99-102 - PubMed
  70. Codas. 2018 Oct 04;30(5):e20170200 - PubMed
  71. Ann Intern Med. 2000 May 2;132(9):743-56 - PubMed
  72. Depress Anxiety. 2019 Mar;36(3):198-212 - PubMed
  73. J Speech Hear Disord. 1978 Feb;43(1):47-57 - PubMed
  74. Mov Disord. 2016 Aug;31(8):1125-33 - PubMed
  75. J Neurosci. 2014 May 14;34(20):6874-8 - PubMed
  76. Behav Neurosci. 2010 Dec;124(6):868-72 - PubMed
  77. Mov Disord. 2014 Jul;29(8):967-75 - PubMed
  78. Parkinsons Dis. 2012;2012:850596 - PubMed
  79. Lancet Neurol. 2006 Mar;5(3):235-45 - PubMed
  80. Dysphagia. 2018 Dec;33(6):749-758 - PubMed
  81. Med Hypotheses. 2010 Dec;75(6):544-6 - PubMed
  82. Mov Disord. 2015 Feb;30(2):229-37 - PubMed
  83. Behav Brain Res. 2007 Sep 4;182(2):284-9 - PubMed
  84. Acta Med Port. 2014 May-Jun;27(3):372-82 - PubMed
  85. Behav Neurol. 1998;11(3):131-137 - PubMed
  86. Front Behav Neurosci. 2012 Jul 25;6:48 - PubMed
  87. Br J Psychiatry. 1969 Dec;115(529):1411-2 - PubMed
  88. J Neurosci. 2011 Apr 27;31(17):6277-88 - PubMed
  89. J Comp Psychol. 2002 Mar;116(1):73-82 - PubMed
  90. Neurology. 1996 Jun;46(6):1548-51 - PubMed
  91. Neuropsychopharmacology. 2012 Feb;37(3):808-21 - PubMed
  92. Neurobiol Dis. 2014 Oct;70:190-203 - PubMed
  93. Neurology. 2009 Nov 17;73(20):1699-704 - PubMed
  94. Curr Opin Otolaryngol Head Neck Surg. 2008 Jun;16(3):205-10 - PubMed
  95. J Gerontol A Biol Sci Med Sci. 2021 Jan 18;76(2):244-252 - PubMed
  96. Behav Brain Res. 2020 Jan 13;377:112175 - PubMed
  97. J Neurosci Res. 2015 Nov;93(11):1713-27 - PubMed
  98. Neurology. 2010 Aug 3;75(5):448-55 - PubMed
  99. Pharmacol Biochem Behav. 2012 Jan;100(3):607-15 - PubMed
  100. Intern Med. 2013;52(5):539-45 - PubMed
  101. NeuroRehabilitation. 2009;24(2):131-44 - PubMed
  102. Eur J Clin Pharmacol. 1977 Jul 19;11(6):443-8 - PubMed
  103. J Voice. 2010 Jul;24(4):477-89 - PubMed
  104. Behav Neurosci. 2000 Oct;114(5):983-90 - PubMed
  105. Behav Neurosci. 2018 Aug;132(4):269-283 - PubMed
  106. J Anxiety Disord. 2018 Jun;57:48-56 - PubMed
  107. J Speech Hear Res. 1969 Sep;12(3):462-96 - PubMed
  108. Br J Sports Med. 1996 Sep;30(3):238-42 - PubMed

Publication Types

Grant support